BR0211060A - Formulação lìquida compreendendo cetuximab e um éster de ácido graxo de polioxietileno sorbitano - Google Patents

Formulação lìquida compreendendo cetuximab e um éster de ácido graxo de polioxietileno sorbitano

Info

Publication number
BR0211060A
BR0211060A BR0211060-1A BR0211060A BR0211060A BR 0211060 A BR0211060 A BR 0211060A BR 0211060 A BR0211060 A BR 0211060A BR 0211060 A BR0211060 A BR 0211060A
Authority
BR
Brazil
Prior art keywords
cetuximab
fatty acid
acid ester
polyoxyethylene sorbitan
sorbitan fatty
Prior art date
Application number
BR0211060-1A
Other languages
English (en)
Inventor
Hanns-Christian Mahler
Robert Mueller
Ulrike Martini-Marr
Udo Haas
Christiane Bachmann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0211060A publication Critical patent/BR0211060A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçãO LìQUIDA COMPREENDENDO CETUXIMAB E UM éSTER DE áCIDO GRAXO DE POLIOXIETILENO SORBITANO". A invenção refere-se a uma formulação farmacêutica líquida estável compreendendo Cetuximab<32>, um anticorpo monocional quimérico contra o receptor de fator de crescimento endotelial (receptor de EGF). A formulação tem estabilidade em armazenamento maior e pode ser usada parenteralmente para o tratamento de tumores.
BR0211060-1A 2001-07-13 2002-06-18 Formulação lìquida compreendendo cetuximab e um éster de ácido graxo de polioxietileno sorbitano BR0211060A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10133394A DE10133394A1 (de) 2001-07-13 2001-07-13 Flüssige Formulierung enthaltend Cetuximab
PCT/EP2002/006696 WO2003007988A1 (de) 2001-07-13 2002-06-18 Flüssige formulierung enthaltend cetuximab und einen polyoxyethylensorbitanfettsäureester

Publications (1)

Publication Number Publication Date
BR0211060A true BR0211060A (pt) 2004-07-20

Family

ID=7691220

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211060-1A BR0211060A (pt) 2001-07-13 2002-06-18 Formulação lìquida compreendendo cetuximab e um éster de ácido graxo de polioxietileno sorbitano

Country Status (18)

Country Link
US (1) US20040170632A1 (pt)
EP (1) EP1406658A1 (pt)
JP (1) JP2004536129A (pt)
KR (1) KR20040018458A (pt)
CN (1) CN1231264C (pt)
AR (1) AR039358A1 (pt)
BR (1) BR0211060A (pt)
CA (1) CA2453342A1 (pt)
CZ (1) CZ2004189A3 (pt)
DE (1) DE10133394A1 (pt)
HU (1) HUP0401046A3 (pt)
MX (1) MXPA04000340A (pt)
PE (1) PE20030433A1 (pt)
PL (1) PL364599A1 (pt)
RU (1) RU2004102395A (pt)
SK (1) SK862004A3 (pt)
WO (1) WO2003007988A1 (pt)
ZA (1) ZA200401161B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3417875T1 (sl) 2003-02-10 2021-01-29 Biogen Ma Inc. Formulacija imunoglobulina in metode za njegovo pripravo
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
CA2555791A1 (en) * 2004-02-12 2005-08-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Highly concentrated liquid formulations of anti-egfr antibodies
RU2408387C2 (ru) * 2004-04-27 2011-01-10 Веллстат Байолоджикс Корпорейшн Лечение злокачественного новообразования с применением вирусов и камптотецинов
JP2008519757A (ja) * 2004-11-12 2008-06-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗ｅｇｆｒ抗体の固形物
AU2006217692A1 (en) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Novel combinational use of sulfonamide compound
CN101415422B (zh) 2006-02-09 2012-11-07 第一三共株式会社 抗癌药用组合物
EP2015775B1 (en) 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
TW200831129A (en) * 2006-10-06 2008-08-01 Amgen Inc Stable formulations
CL2007002881A1 (es) * 2006-10-20 2008-05-09 Amgen Inc Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodo
CN107773755B (zh) * 2016-08-31 2021-06-22 上海津曼特生物科技有限公司 抗表皮生长因子受体单克隆抗体的注射液制剂
EP3624846B1 (en) 2017-05-16 2024-08-07 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan
JP2020002130A (ja) * 2018-06-25 2020-01-09 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
US20210290644A1 (en) * 2018-08-31 2021-09-23 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
WO1996040210A1 (en) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
AU716785B2 (en) * 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation

Also Published As

Publication number Publication date
US20040170632A1 (en) 2004-09-02
JP2004536129A (ja) 2004-12-02
CN1527724A (zh) 2004-09-08
SK862004A3 (en) 2004-07-07
RU2004102395A (ru) 2005-05-27
AR039358A1 (es) 2005-02-16
CZ2004189A3 (cs) 2004-05-12
MXPA04000340A (es) 2004-05-04
CA2453342A1 (en) 2003-01-30
EP1406658A1 (de) 2004-04-14
WO2003007988A1 (de) 2003-01-30
HUP0401046A3 (en) 2006-11-28
PE20030433A1 (es) 2003-05-24
ZA200401161B (en) 2004-10-22
KR20040018458A (ko) 2004-03-03
HUP0401046A2 (en) 2006-04-28
PL364599A1 (en) 2004-12-13
CN1231264C (zh) 2005-12-14
DE10133394A1 (de) 2003-01-30

Similar Documents

Publication Publication Date Title
BR0211060A (pt) Formulação lìquida compreendendo cetuximab e um éster de ácido graxo de polioxietileno sorbitano
BR0215266A (pt) Preparação liofilizada compreendendo anticorpos contra o receptor de egf
UY27320A1 (es) Nuevas composiciones farmacéuticas
BRPI0416986A (pt) preparação farmacêutica compreendendo um anticorpo contra o receptor de egf
ATE464062T1 (de) Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
ATE427925T1 (de) Phenoxycarbonsaureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
CO5660273A2 (es) Formulaciones de proteina y anticuerpo de alta concentracion
SE0100901D0 (sv) New composition
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
NO330934B1 (no) Flytende farmasoytisk preparat samt anvendelse og fremstilling derav.
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
BR0209777A (pt) Formulações lìquidas estáveis
WO2004006959A8 (en) Liquid dosage compositions of stable nanoparticulate active agents
NO20052520L (no) Nye sulfamider
EA200800731A1 (ru) Жидкие составы гербицидов на основе сульфонилмочевины
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
DE60037726D1 (de) Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
AP2003002742A0 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
ATE301654T1 (de) Naphthyridinderivate
NO20031159D0 (no) Melkesyrebakterier som er i stand til å redusere et individs tendens til åutvikle allergiske reaksjoner
MY127749A (en) Liquid formulation
ATE277923T1 (de) Propansäurederivate, die die bindung von integrinen an ihre rezeptoren behindern
EP1466602A4 (en) ORGAN FIBROSIS INHIBITORS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2029 DE 24/11/2009.